Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 0.49 |
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.49 |
| ▸ | SLC6A3 known ✓ | Q01959 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.97 |
| ▸ | RAB9A | P51151 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11038376 | 1.00 | NPC1 (0.97) | NPC1RAB9AMAPK1KDM4EMAPT | |
| SCHEMBL11040777 | 0.99 | NPC1 (1.00) | NPC1RAB9AMAPK1KDM4EMAPT | |
| SCHEMBL29389716 | 0.99 | NPC1 (1.00) | NPC1RAB9AMAPK1KDM4EMAPT | |
| Bromide SCHEMBL11038410 | 0.83 | NPC1 (0.68) | NPC1RAB9AMAPK1KDM4EMAPT | |
| Bromide SCHEMBL11038664 | 0.82 | NPC1 (0.67) | NPC1RAB9AMAPK1KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL11040607 | 0.80 | NPC1 (0.68) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11050238 | 0.80 | NPC1 (0.68) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11006639 | 0.78 | NPC1 (0.65) | NPC1RAB9AMAPK1KDM4EMAPT | |
| Bromide SCHEMBL11268045 | 0.78 | SLC6A2 (0.65) | NPC1RAB9ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11038643 | 0.77 | NPC1 (0.64) | NPC1RAB9ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-02-29 | — | — | US | disclosed |
| WO-2022099195-A1 | OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240065999-A1 | Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents | SLC6A3, SLC18A2, SLC6A2 | SLC6A2 3/4885SLC6A4 8/4885SLC6A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.